menu
    • menu
    [{"orgOrder":0,"company":"Akorn Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cetrorelix Acetate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Akorn Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akorn Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akorn Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Akorn Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cetrorelix Acetate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Akorn Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akorn Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akorn Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Calyptus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cetrorelix Acetate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Calyptus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Calyptus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calyptus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Calyptus Pharmaceuticals","sponsor":"Provepharm Life Solutions","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Cetrorelix Acetate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Calyptus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Calyptus Pharmaceuticals \/ Provepharm Life Solutions","highestDevelopmentStatusID":"15","companyTruncated":"Calyptus Pharmaceuticals \/ Provepharm Life Solutions"},{"orgOrder":0,"company":"Fresenius SE & Co. KGaA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cetrorelix Acetate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Fresenius SE & Co. KGaA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius SE & Co. KGaA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius SE & Co. KGaA \/ Inapplicable"},{"orgOrder":0,"company":"Apotex Fermentation Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cetrorelix Acetate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Apotex Fermentation Inc.","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apotex Fermentation Inc. \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apotex Fermentation Inc. \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Cetrorelix

    Menu

    Cetrorelix

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Fresenius SE & Co. KGaA

                            Germany arrow
                            Coatings Trends
                            Not Confirmed

                            Fresenius SE & Co. KGaA

                            Germany arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cetrorelix Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Fresenius Kabi Expands Women's Health with New Reproductive Health Generic

                            Details : Cetrorelix Acetate for Injection is a synthetic decapeptide with GnRH antagonist, indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation.

                            Product Name : Cetrotide-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 27, 2024

                            Lead Product(s) : Cetrorelix Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Apotex Fermentation Inc.

                            Canada arrow
                            Coatings Trends
                            Not Confirmed

                            Apotex Fermentation Inc.

                            Canada arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cetrorelix Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Apotex Corp. Launches Generic Fertility Treatment Injectable Cetrorelix® in the US

                            Details : Cetrorelix Acetate for Injection is a synthetic decapeptide with GnRH antagonist, indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation.

                            Product Name : Cetrotide-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 14, 2024

                            Lead Product(s) : Cetrorelix Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Akorn Pharmaceuticals

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed

                            Akorn Pharmaceuticals

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cetrorelix Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Akorn Introduces FDA-approved Generic Cetrorelix Acetate for Injection 0.25 mg at ASRM

                            Details : Cetrorelix Acetate is used to prevent premature ovulation during controlled ovarian stimulation. Cetrorelix blocks the effects of a natural hormone, called GnRH. GnRH controls the secretion of another hormone, called LH, which induces ovulation during th...

                            Product Name : Cetrorelix Acetate-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 27, 2022

                            Lead Product(s) : Cetrorelix Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Calyptus Pharmaceuticals

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed

                            Calyptus Pharmaceuticals

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cetrorelix Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Sponsor : Provepharm Life Solutions

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Calyptus Pharmaceuticals Announces Partnership with Provepharm to Accelerate Development of an Acute Care Inje...

                            Details : Provepharm acquired global rights of the Cetrorelix acetate from Calyptus and will take on all development activities and ultimately commercial distribution upon approval.

                            Product Name : Cetrorelix Acetate-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            August 22, 2022

                            Lead Product(s) : Cetrorelix Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Sponsor : Provepharm Life Solutions

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Calyptus Pharmaceuticals

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed

                            Calyptus Pharmaceuticals

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cetrorelix Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Calyptus Pharmaceuticals Announces FDA Approval of Cetrorelix Acetate for Injection, 0.25 mg/vial

                            Details : Cetrorelix Acetate for Injection, 0.25 mg/vial is indicated for the inhibition of premature luteinizing hormone surges in women undergoing controlled ovarian stimulation.

                            Product Name : Cetrorelix Acetate-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 19, 2022

                            Lead Product(s) : Cetrorelix Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Akorn Pharmaceuticals

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed

                            Akorn Pharmaceuticals

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cetrorelix Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Akorn Announces FDA-Approved Generic Cetrorelix Acetate for Injection 0.25 mg

                            Details : Cetrorelix Acetate for Injection 0.25 mg is used to prevent premature ovulation during controlled ovarian stimulation, for Injection blocks such undesirable premature ovulation.

                            Product Name : Cetrorelix Acetate-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 16, 2022

                            Lead Product(s) : Cetrorelix Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            University of Oxford

                            United Kingdom arrow
                            Coatings Trends
                            Not Confirmed

                            University of Oxford

                            United Kingdom arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cetrorelix Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase IV

                            Sponsor : Oxford Fertility Limited

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Frozen Embryo Transfer With GnRH-antagonist Trial

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 04, 2018

                            Lead Product(s) : Cetrorelix Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase IV

                            Sponsor : Oxford Fertility Limited

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Merck Group

                            Germany arrow
                            Coatings Trends
                            Not Confirmed

                            Merck Group

                            Germany arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cetrorelix Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase III

                            Sponsor : Merck Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Tech...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 20, 2010

                            Lead Product(s) : Cetrorelix Acetate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase III

                            Sponsor : Merck Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth